The Clinical significance of serum synaptophysin like 1 protein levels in breast cancer
SYLP-1 and breast cancer
Abstract
Background: Mammography, used for breast cancer (BC) screening, has limitations such as decreased sensitivity in dense breasts. Currently used tumor markers are insufficient in diagnosing breast cancer. In this study, we aimed to investigate the relationship between serum levels of synaptophysin-like protein 1 (SYPL1) and BC, as well as compare SYPL1 with other blood tumor markers. Method: The study group consisted of 80 female patients with a histopathological diagnosis of invasive BC and didn’t receive any radiotherapy/chemotherapy. The control group 72 women with noprevious history of breast disease and evaluated as Breast Imaging Reporting and Data Systems (BI-RADS 1-2) on imaging. Serum SYPL1, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) were measured in both groups. Results: The diagnostic values of SYPL1, CEA and CA15-3 proteins in diagnosing BC were statistically significant. The sensitivity of SYPL1 was 48.75%, with a specificity of 80.56%. CA15-3 had a sensitivity of 80% and a specificity of 49.30%. There wasn’t statistically significant correlation between serum SYPL1 and tumor diameter, lymph node metastasis, distant organ metastasis, and stage.
Conclusion: The serum SYPL1 maintained a higher discriminatory ability for BC. The serum SYPL1 level can be used with high specificity in the diagnosis of BC. Although SYPL1 has low diagnostic value in BC by itself.
References
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7–30.
2. Ban KA, Godellas CV. Epidemiology of breast cancer. Surg Oncol Clin N Am. 2014; 23:409-22.
3. Tryggvadóttir L, Tulinius H, Eyfjord JE, Sigurvinsson T. Breastfeeding and reduced risk of breast cancer in an Icelandic cohort study. Am J Epidemiol. 2001;154:37-4.
4. Nelson HD, Zakher B, Cantor A, Fu R, Griffin J, et al. Risk factors for breast cancer for women aged 40 to 49 years: a systematic review and meta-analysis. Ann Intern Med. 2012;156:635-48.
5. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004;13:220-4.
6. Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021;146:30-47.
7. Zubair M, Wang S, Ali N. Advanced Approaches to Breast Cancer Classification and Diagnosis. Front Pharmacol. 2021;11:632079.
8. Windoffer R, Borchert-Stuhlträger M, Haass NK, Thomas S, Hergt M, Bulitta CJ, et al. Tissue expression of the vesicle protein pantophysin. Cell Tissue Res. 1999; 296: 499–510.
9. Liu L, He Q, Li Y, Zhang B, Sun X, Shan J, Pan B, Zhang T, Zhao Z, Song X, Guo Y. Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer. Clin Chim Acta. 2020;509:36-42.
10. Kasprzak A, Zabel M, Biczysko W. Selected markers (chromogranin A, neuron-specific enolase, synaptophysin, protein gene product 9.5) in diagnosis and prognosis of neuroendocrine pulmonary tumours. Pol J Pathol. 2007;58:23-33.
11. Kowalski DM, Krzakowski M, Jaśkiewicz P, Olszewski W, Janowicz-Żebrowska A, Wojas-Krawczyk K, Krawczyk P. Prognostic value of synaptophysin and chromogranin a expression in patients receiving palliative chemotherapy for advanced non-small-cell lung cancer. Respiration. 2013;85:289-96.
12. Chen DH, Wu QW, Li XD, Wang SJ, Zhang ZM. SYPL1 overexpression predicts poor prognosis of hepatocellular carcinoma and associates with epithelial-mesenchymal transition. Oncol Rep. 2017;38:1533-1542.
13. Yang C, Wang Y. Identification of differentiated functional modules in papillary thyroid carcinoma by analyzing differential networks. J Cancer Res Ther. 2018 Dec;14(Supplement):S969-S974.
14. Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science (80-) [Internet]. 2017;357(6352). Available from: https://www.proteinatlas.org/ENSG00000008282-SYPL1/pathology.
15. Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Res. 2015;17(1):1–12.
16. Vourtsis A, Berg WA. Breast density implications and supplemental screening. Eur Radiol. 2019;29(4):1762–77.
17. Woosung N, Joon L, Seeyoun J, Jungeun L, Heungkyu C, Yong P, et al. The prognostic significance of preoperative tumor marker (CEA, CA153 ) elevation in breast cancer patients : data from the Korean Breast Cancer Society Registry. Breast Cancer Res Treat [Internet]. 2019;(0123456789).
18. Fu Y, Li H. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients : A Meta-Analysis META-ANALYSIS. 2016;3154–62.
19. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Determination of the prognostic value of preoperative CA15 3 and CEA in predicting the prognosis of young patients with breast cancer. Oncol Lett. 2018;16(4):4679–88.
20. Penault-Llorca F, Radosevic-Robin N. Ki67 assessment in breast cancer: an update. Pathology. 2017;49:166–71.
21. Moon PG, Lee JE, Cho YE, Lee SJ, Jung JH, Chae YS, Bae HI, Kim YB, Kim IS, Park HY, Baek MC. Identification of Developmental Endothelial Locus-1 on Circulating Extracellular Vesicles as a Novel Biomarker for Early Breast Cancer Detection. Clin Cancer Res. 2016;22:1757-66.
22. Prunotto M, Farina A, Lane L, Pernin A, Schifferli J, Hochstrasser DF, et al. Proteomic analysis of podocyte exosome-enriched fraction from normal human urine. J Proteomics [Internet]. 2013;82:193–229.
Copyright (c) 2023 Hafize Uzun, Yagmur Ozge Turac Kosem, Mehmet Velidedeoglu, Pınar Kocael , Seyma Dumur , Osman Simsek
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.